AKT1 and breast carcinoma: In contrast, the MNI combination of sapanisertib plus serabelisib generally showed a greater inhibition of S6 and AKT phosphorylation and substantially greater inhibition of 4E-BP1 phosphorylation in endometrial and breast cancer cells.